References
- Sarlio-Lahteenkorva S, Stunkard A, Rissanan A. Psychosocial factors and quality of life in obesity. Int. J. Obes. Relat. Metab. Disonl 19\(Suppl. 6), S1—S5 (1995).
- •Addresses the stigma of being overweight and its ill effects.
- Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JR The continuing epidemics of obesity and diabetes in the United States. JAIVIA 286, 1195–1200 (2001).
- Kawachi I. Physical and psychological consequences of weight gain. J. Gun. Psychiatry60\(Suppl. 21), 5–9 (1999).
- •Includes discussion of weight gain and individual causes of increased morbidity.
- National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the Evidence Report. Obes. Res. 6\(Suppl. 2), S51—S209 (1998).
- ••Comprehensive, evidence-based guidelinesfor the treatment of overweight and obesity with a focus on the role of the primary care provider.
- Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes. Rev. 2, 173–182 (2001).
- •Good review of the effect of obesity on health-related quality of life.
- Yancy WS Jr, Olsen MK, Westman EC, Bosworth HB, Edelman D. Relationship between obesity and health-related quality of life in men. Obes. Res. 10,1057–1062 (2002).
- Allison DB, Fontaine KR, Heo M eta]. The distribution of body mass index among individuals with and without schizophrenia. j Gun. Psychiaby60,215–220 (1999).
- Casey DE. The relationship of pharmacology to side effects. j PFhiatry58\(Suppl. 10), 55–62 (1997).
- Collaborative Working Group on Clinical Trials Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials.' Gun. PFhiatry59\(Suppl. 12), 23–27 (1998).
- Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. j Gun. fiychiatry62\(Suppl. 7), 22–31 (2001).
- Allison DB, Mentore JL, Heo M eta]. Antipsychotic-induced weight gain: a comprehensive research synthesis. Aim PFhiatry156,1686–1696 (1999).
- ••Comprehensive review of research literature regarding the amount of weight gain associated with individual antipsychotic agents.
- Masand PS, Gupta S. Long-term adverse effects of novel antipsychotics. I liychiatric Pract. 6,299–309 (2000).
- Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J. fiychiab: Res. 35,187-191 (2001).
- •Good summary of the data regarding off-label indications for atypical antipsychotics including randomized controlled studies and case reports.
- Collaborative Working Group on Clinical Trials Evaluations. Adverse effects of the atypical antipsychotics. I Gun. Psychiatry 59\(Suppl. 12), 17–22 (1998).
- Baptista T Body weight induced by antipsychotic drugs: mechanisms and management. Acta. PTchiatt: Scan. 100,3–16 (1999).
- Kalucy RS. Drug-induced weight gain. Drugs 19,268–278 (1980).
- ••Excellent review of drug-induced weightgain including mechanisms of weight gain.
- Kurzthaler D, Fleischhacker WW The clinical implications of weight gain in schizophrenia. J. Gun. liychiatry 62 (Suppl. 7), 32–37 (2001).
- Perkins DO. Adherence to antipsychotic medications. J. Gun. Psychiatry 60 (Suppl. 21), 25–30 (1999).
- Henderson DC, Cagliero E, Gray C etal. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a 5 year naturalistic study. AM. I PFhiatry157,975–981 (2000).
- Csemansky JG, Mahmoud R, Brenner R for the Risperidone-USA-70 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl. J. Merl 346,16–22 (2002).
- Geodon prescribing information. Pfizer Inc, NY, USA, June (2002).
- Jody D, Saha AR, Iwamoto T eta]. Meta- analysis of weight effects with aripiprazole. Int. J. Neuropsychopharmacol 5 (Suppl. 1), S186 (2002).
- Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related healths factors in schizophrenia. J. fiychiatry62, 92–100 (2001).
- Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis and Type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J. Clin. PFhiatry 62 (Suppl. 27), 10–14 (2001).
- •Summary of clinical experience with glucose metabolism impairment in patients treated with atypical antipsychotics.
- Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Phatmacopsychiatry35, 205–219 (2002).
- •Reviews the clinical features of antipsychotic-induced body weight gain, the mechanisms involved in weight gain and metabolic dysregulation and strategies to prevent and treat these adverse effects.
- Wang GJ, Volkow ND, Logan J eta]. Brain dopamine and obesity. Lancet 357,354–357 (2001).
- Reynolds GP, Zhang Z, Zhang X. Association of antipsychotic drug induced weight gain with a 5HT2C receptor gene polymorphism. Lancet 359,2086-2087 (2002).
- Meyer J. Effects of atypical antipsychotics on weight and serum lipids. J. Clin. PFhiatry 62 (Suppl. 27), 27–34 (2001).
- Kroeze WK, Hufeisen SJ, Popadak BA etal Hl-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28,519–526 (2003).
- Masand PS. Relative weight gain among antipsychotics. I Clin. Psychiab y60, 706–708 (1999).
- Wetterling T Bodyweight gain with atypical antipsychotics: a comparative review. Drug- Sal 24,59–73 (2001).
- Schmidt AW, Lebel LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. I Pharmacol 25,197–201 (2001).
- Ackerman S, Nolan U. Bodyweight gain induced by psychotropic drugs: incidence, mechanisms and management. CNS Drugs 9,135–151 (1998).
- Masand PS. Weight gain associated with psychotropic drugs. Expert Opin. Phatmacother. 1,377–389 (2000).
- ••Comprehensive review of various types ofpsychotropic drugs and their propensity to cause clinically significant weight gain.
- Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated in-patients: metabolic outcomes after 1 year. J. Clin. PTchiatry63, 4525–4433 (2002).
- Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. I Psychiaby156, 1417–1420 (1999).
- McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia: a preliminary study.j Clin. Hasp. Pharm. 11, 297–299 (1986).
- Mukherjee S, Decina P, Bocola V eta]. Diabetes mellitus in schizophrenic patients. Compr. fiychiatry37, 68–73 (1996).
- Gupta S, Steinmeyer C, Frank B eta]. Hyperglycemia and hyperlipidemia in real world patients on antipsychotic therapy. Am. J. Therapeutics (2003) (In Press).
- Martina CMR, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry160, 284–289 (2003).
- Dixon L, Weiden P, Delahanty J etal Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 26, 903–912 (2000).
- Liebzeit K, Markowitz J, Caley C. New onset diabetes and atypical antipsychotics. Eur. Neuropsychopharmacol 11, 25–32 (2001).
- Henderson DC. Clozapine: diabetes mellitus, weight gain and lipid abnormalities. J. Clin. Psychiatry 62 (Suppl. 23), 39–44 (2001).
- Haupt D, Newcomer J. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 62 (Suppl. 27), 15–26 (2001).
- Wirshing DA, Pierre JM, Eyeler J etal Risperidone-associated new-onset diabetes. Biol. Psychiab y50, 148–149 (2001).
- Jin H, Meyer JM, Jeste D. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 14, 59–64 (2002).
- Koller EA, Doraiswamy PM. Olanzapine- associated diabetes mellitus. Pharmacotherapy22, 841–852 (2002).
- Masand PS. Atypical Antipsychotics and DKA: Issues and Controversies Thomson Professional Postgraduate Services. 1(2), 2002.
- Wirshing DA, Spellberg BJ, Erhart SM et al Novel antipsychotics and new-onset diabetes. Biol. Psychiatry 44, 778–783 (1998).
- ••Report of six cases of clozapine- andolanzapine-associated diabetes mellitus as well as a brief review of the literature on this topic.
- American Diabetes Association. Diabetic nephropathy. Diabetes Care 25\(Suppl. 1), S85—S89 (2002).
- American Diabetes Association. National standards for diabetes self-management education. Diabetes Care 25\(Suppl. 1), S140—S147 (2002).
- Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. Ann. Intern. Med. 67, 48–59 (1967).
- Huang Z, Willett WC, Manson JE eta]. Body weight, weight changes and risk for hypertension in women. Ann. Intern. Med. 128, 81–88 (1998).
- Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change and coronary heart disease in women: risk within the normal weight range. JAMA 273, 461–465 (1995).
- Grundy SM, Becker D, Clark LT et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486– 2497 (2001).
- Doering S, Muller E, Kopcke W et al Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 24, 419–429 (1998).
- Buis W Patients' opinions concerning side effects of depot neuroleptics. Am. J. PTchtry149, 844–845 (1992).
- Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J. Clin. Psychiatry 50, 127–131 (1989).
- Angermeyer MC, Matschinger H. Neuroleptics and quality of life: a patient survey. Psychiatr. Prax. 27, 64–68 (2000).
- Weiden PJ, Allison DB, Mackell JA, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Presented at the 2000 Annual Meeting of the American Psychiatric Association, Chicago, IL, May 13–18 (2002).
- Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N. Engl. J. Med. 329, 1008–1012 (1993).
- • Identifies the social and economic consequences of being overweight during adolescence and early adulthood.
- Crocker J, Cornwell B, Major B. The stigma of overweight: affective consequences and attributional ambiguity. J. Per. Soc. Psycho" 64, 60–70 (1993).
- Rumpel C, Ingram DD, Harris TB etal The association between weight change and psychological well-being in women. int. J. Obes. 18, 179–183 (1994).
- Sullivan M, Karlsson J, Sjostrom L etal Swedish obese subjects (SOS) — an intervention study of obesity: baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int. J. Obes. Relat. Metab. Disord. 17, 503–512 (1993).
- Fine JT, Colditz GA, Coakley EH et al A prospective study of weight change and health-related quality of life in women. JA /1//A 282, 2136–2142 (1999).
- Damush TM, Stump TE, Clark DO. Body-mass index and 4-year change in health-related quality of life. J. Aging Health 14, 195–210 (2002).
- Larsson U, Karisson J, Sullivan M. Impact of overweight and obesity on health-related quality of life: a Swedish population study. Int. I Relat. .114tab. Did!" 26, 417–424 (2002).
- Masand PS. Weight gain associated with atypical antipsychotics. I PTchotic Db. Rev 2, 4–6 (1998).
- Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15, 537–551 (2001).
- •Comprehensive literature review that assesses various bodyweight gain liabilities associated with atypical antipsychotics and the effects of bodyweight gain on quality of life.
- Masand PS, Berry SL. Switching antipsychotic therapies. Ann. Pharmacother. 34, 200–207 (2000).
- ••Excellent guide to switching antipsychotictherapies including reasons, when and how to switch.
- Nguyen CT, Ortiz T, Franklin D et al Nutritional education in minimizing weight gain with antipsychotic therapy. Proceedings of the American Psychiatric Association, LA, USA (2001).
- Bustillo JR, Lauriello J, Parker K etal Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology28, 527–529 (2003).
- Poyurovsky M, Pashinian A, Gil-Ad I et al Olanzapine-induced weight gain in patients with first episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J. PTchiatry159, 1058–1060 (2002).
- Poyurovsky M, Isaacs I, Fuchs C et al Attentuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia : a double-blind, placebo-controlled study. Am. J. Bychiarty160, 297–302 (2003).
- Baptista T, Hernandez L, Alvarez L et al Metformin in obesity associated with antipsychotic drug administration: a pilot study. J. Clin. Psychiatry 62, 653–654 (2001).
- Morrison J, Cottingham E, Barton B. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. PTchiatry159, 655–657 (2002).
- Floris M, Lejeune J, Deberdt W Effect of amantadine on weight gain during olanzapine treatment. Eur. Neuropsychopharmacol 11, 181–182 (2001).
- Gupta S, Masand PS, Frank BL eta]. Topiramate in bipolar and schizoaffective disorders: weight loss and efficacy. Primary Carr Compan/oni Gun. Psychiatry 2,96–100 (2000).
- Breier A. Tanaka Y, Roychowdhury S. Nizatidine ameliorates olanzapine treatment-related weight gain. International Congress on Schizophrenia Research, Indianapolis, IN, USA (2002).
- Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol. Psychiatry48, 167–168 (2000).
- Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int. Gun. PTchopharmacol 17, 145–160 (2002).
Websites
- Marketing Authorization Appilication, AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA www.seroquel.com/profasp/details/ wao_weightpro.asp. Data on file. (Accessed February 12, 2003).
- American Affiliations Diabetes Association. Facts and figures: the impact of diabetes. www.diabetes.org/mainlapplicationl-commercewf. (Accessed December 18, 2002).